GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Main finding · All thyroid cancerResult — go to the resultAdjusted hazard ratio 1.58 95% CI 1.27–1.95Authors' conclusion
In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment.
Study context
- Population
- Individuals with T2D treated with second-line antidiabetes drugs 2006–2018, French SNDS databasenested case-control
- Participants
- 2,562 vs 45,184
- Comparison
- GLP-1 receptor agonists (RA) use vs no use
- Casen = 2,562
- Controln = 45,184reference
- Outcome
- Thyroid cancer (all; medullary) by GLP-1 RA exposure within 6 years before a 6-month lag, as current use and cumulative duration (≤1, 1 to 3, >3 years)
Methodological detailsFrench national health care insurance system (SNDS) database, matched with up to 20 controls on age, sex and length of diabetes, risk-set sampling, conditional logistic regression
- French national health care insurance system (SNDS) database
- Matched with up to 20 controls on age, sex and length of diabetes
- Risk-set sampling
- Conditional logistic regression
Main finding
All thyroid cancer
Adjusted hazard ratio
1.58
95% CI 1.27–1.95
GLP-1 RA use (by cumulative duration)vs no use
adjusted HR 1.58 (95% CI 1.27–1.95)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Medullary thyroid cancer
| Adjusted HR (95% CI) | ||
|---|---|---|
| GLP-1 RA 1-3 yearsIncreased risk | 1.78 (1.04–3.05) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Original publication
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. Published 10 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →